The detailed information for PTAB case with proceeding number PGR2021-00039 filed by Merck Sharp & Dohme Corp. against Genentech, Inc. on Jan 20, 2021. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.
| Document Name | Filing Date | Category | Filing Party |
|---|---|---|---|
Alert me when new update on this case | |||
Rehearing: DECISION Denying Petitioner’s Request for Rehearing Dismissing Patent Owner’s Motion for Termination 37 C.F.R. §§ 42.71(d), 42.207(e) | Jul 20, 2023 | PAPER | BOARD |
Patent Owner's Motion to Terminate Proceeding | Jul 6, 2023 | PAPER | PATENT OWNER |
Exhibit 2053 | Jul 6, 2023 | EXHIBIT | PATENT OWNER |
Notice of Supplemental Authority | Jun 9, 2023 | PAPER | PETITIONER |
Conduct of the Proceeding Granting Request for Additional Briefing on Supplemental Authority 37 C.F.R. § 42.5 | Jun 2, 2023 | PAPER | BOARD |
Exhibit 3003 | Jun 2, 2023 | EXHIBIT | BOARD |
Petitioner's Updated Mandatory Notices | May 26, 2023 | PAPER | PETITIONER |
Panel Change Order | Apr 27, 2023 | PAPER | BOARD |
Patent Owner's Updated Mandatory Notices | Jan 26, 2023 | PAPER | PATENT OWNER |
Order: Order Denying POP Request | Feb 4, 2022 | PAPER | BOARD |
Notice: notice of receipt of POP request | Jan 28, 2022 | PAPER | BOARD |
E-mail requesting precedential opinion panel review | Sep 3, 2021 | EXHIBIT | BOARD |
Request for Rehearing of Decision Denying Institution | Aug 23, 2021 | PAPER | PETITIONER |
Trial Instituted Document | Jul 24, 2021 | PAPER | BOARD |
Patent Owner's Sur-Reply to Petitioner's Reply to Patent Owner's Preliminary Response to Petition for Post Grant Review of U.S. Patent No. 10,626,174 | May 21, 2021 | PAPER | PATENT OWNER |
Petitioner's Reply to Patent Owner's Preliminary Response | May 14, 2021 | PAPER | PETITIONER |
Conduct of the Proceeding | May 11, 2021 | PAPER | BOARD |
Exhibit 3001 | May 11, 2021 | EXHIBIT | BOARD |
Patent Owner's Preliminary Response to Petition for Post Grant Review of U.S. Patent No. 10,626,174 | Apr 27, 2021 | PAPER | PATENT OWNER |
Blank_PGR | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Nobel Press Release | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Blackburn (2009) | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Intlekofer (2013) | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Kulpa | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Callahan (2013) | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Brahmer | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US8728474 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US8008449 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US7943743 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US7488802 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
WO2009114335A2 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US8168757 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Butte 2007 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
IPR2016-01217 - Petition (999) | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT01295827 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US9220776 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US9499596 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
CN103073644B58285_en-US | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Stanietsky (2009) | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Stanietsky Supporting Information | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Lozano (2012) | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Yu (2009) | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Chen and Mellman | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Johnston et al. | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Genentech_ Press Releases _ Monday, Jan 4, 2021 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04262856 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04047862 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04570839 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04543617 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04256421 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04294810 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT03708224 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04736173 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Frequently Asked Questions_ Breakthrough Therapies _ FDA | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04305041 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04305054 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
NCT04303169 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Sept. 20 Release | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
PTAB-IPR2016-01219-12 Corrected Petition | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
WO2001014557A1 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
EP3214095B1 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Merck Letter | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
MSD 7.1 Disclosure 1 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US20190270802A1 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US10766957 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
WO2013079174A1 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US9970944 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US8795666 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US9994637 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
[Part 1] 15239524 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
[Part 2] 15239524 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
[Part 3] 15239524 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
[Part 4] 15239524 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
[Part 5] 15239524 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
[Part 6] 15239524 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
[Part 7] 15239524 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
US20140341902A1 | Apr 27, 2021 | EXHIBIT | PATENT OWNER |
Patent Owner's Mandatory Notices | Jan 28, 2021 | PAPER | PATENT OWNER |
Patent Owner's Power of Attorney | Jan 28, 2021 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Jan 27, 2021 | PAPER | BOARD |
US 10,626,174 | Jan 20, 2021 | EXHIBIT | PETITIONER |
File History US 10,626,174 (1 of 2) | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 14/333,375 | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 61/846,941 | Jan 20, 2021 | EXHIBIT | PETITIONER |
File History US 10,626,174 (2 of 2) | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 61/950,754 | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 61/985,884 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Pauken et al. (2014) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Huston et al. (1988) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Janeway et al. (2001) Ch. 3 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Frank (2002) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Roitt (1997) Ch. 6 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Ponomarenko & Bourne (2007) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Pedotti et al. (2011) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Vaughan et al. (1996) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Pardoll (2012) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Smothers et al. (2013) | Jan 20, 2021 | EXHIBIT | PETITIONER |
BLA Approval of Bavencio (avelumab) (2017) | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 61/865,582 | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 61/992,109 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Alberts et al. (2002) Ch. 24 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Janeway et al. (2001) Ch. 4 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Roitt (1997) Ch. 5, 80 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Van Regenmortel (2014) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Griffiths et al. (1993) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Hoogenboom et al. (1991) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Marks et al. (1991) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Carmen & Lutz (2002) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Dorlands Illustrated Med. Dict. (2007) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Kandoth et al. (2013) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Johnston et al. (2014) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Written Description Guidance For Antibody Claims (2018) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Prembrolizumab USAN Statement (2013) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Floudas et al. (2019) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Fessas et al. (2017) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Lee et al. (2017) | Jan 20, 2021 | EXHIBIT | PETITIONER |
BLA Approval for Cemiplimab-rwlc (LIBTAYO) (2018) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Jure-Kunkel et al. (2013) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Mak et al. (2014) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Duffy et al. (2016) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Gao et al. (2016) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Genentech EP3208612B1 | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 2009/0258013 (Clark) | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 2010/0203056 (Irving) | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Nivolumab | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Pembrolizumab | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Pidilizumab | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Cemiplimab | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Dostarlimab | Jan 20, 2021 | EXHIBIT | PETITIONER |
Gajewski et al. (2011) | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Atezolizumab | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Durvalumab | Jan 20, 2021 | EXHIBIT | PETITIONER |
Chatterjee et al. (2016) | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 8,217,149 | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/mAb-DB result for PD-L1 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Powderly et al. (2017) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Lelliott et al. (2019) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Zhao et al. (2017) | Jan 20, 2021 | EXHIBIT | PETITIONER |
US 2010/0316646 (Gao) | Jan 20, 2021 | EXHIBIT | PETITIONER |
PCT WO2006/121168 | Jan 20, 2021 | EXHIBIT | PETITIONER |
PCT WO2009/101611 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Goding et al. (2013) | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Retifanlimab | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Sasanlimab | Jan 20, 2021 | EXHIBIT | PETITIONER |
Ji et al. (2011) | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/mAb-DB result for PD-1 | Jan 20, 2021 | EXHIBIT | PETITIONER |
INN WHO Drug Information (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Zhang et al. (2017) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Cho et al. (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Guzik et al. (2019) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Selby et al. (2016) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Deschoolmeester et al. (2011) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Masugi et al. (2017) | Jan 20, 2021 | EXHIBIT | PETITIONER |
McKean et al. (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Tislelizumab | Jan 20, 2021 | EXHIBIT | PETITIONER |
LIBTAYO Prescribing Information (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Press Release BusinessWire (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Wang et al. (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Mahmoud et al. (2011) | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Spartalizumab | Jan 20, 2021 | EXHIBIT | PETITIONER |
Press Release GlaxoSmithKline PLC (2019) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Al-Khami et al. (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Naing et al. (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
PCT WO2007/005874 | Jan 20, 2021 | EXHIBIT | PETITIONER |
PCT WO2017/007985 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Press Release Bristol Myers Squibb (2009) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Press Release Fortress Biotech (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Press Release PRNewsWire (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Wu et al. (2021) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Lim et al. (2018) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Zost et al. (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Etigilimab | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Vibostolimab | Jan 20, 2021 | EXHIBIT | PETITIONER |
Niu et al. (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
PCT WO2016/106302 | Jan 20, 2021 | EXHIBIT | PETITIONER |
Matkowski et al. (2009) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Nimjee et al. (2017) | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Avelumab | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Cosibelimab | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Sugemalimab | Jan 20, 2021 | EXHIBIT | PETITIONER |
BAVENCIO Prescribing Information (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Lanzavecchia et al. (2007) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Iwai et al. (2002) | Jan 20, 2021 | EXHIBIT | PETITIONER |
Press Release Mereo BioPharma (2020) | Jan 20, 2021 | EXHIBIT | PETITIONER |
IMGT/2Dstructure-DB card for Tiragolumab | Jan 20, 2021 | EXHIBIT | PETITIONER |
Press Release Roche (2021) | Jan 20, 2021 | EXHIBIT | PETITIONER |
PCT WO2018/200430 | Jan 20, 2021 | EXHIBIT | PETITIONER |
McDonnell Declaration | Jan 20, 2021 | EXHIBIT | PETITIONER |
Ravetch Declaration | Jan 20, 2021 | EXHIBIT | PETITIONER |
PGR Petition for U.S. Patent No. 10,626,174 | Jan 20, 2021 | PAPER | PETITIONER |
Power of Attorney for U.S. Patent No. 10,626,174 PGR Petition | Jan 20, 2021 | PAPER | PETITIONER |